Aktis Oncology, Inc.

AKTS · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

–

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders14.1%

Institutions72.9%

Income Statement

	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2016-03-31	2014-07-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$27.38M	$27.12M	$15.35M	$6.62M	$1.79M	$1.44M	$1.21M	–	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$28.07M	$30.24M	$19.49M	$10.65M	$2.41M	$1.01M	$1.02M	–	–
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	-$689000	-$3.12M	-$4.14M	-$4.03M	-$624000	$430000	$188375	–	–
Gross profit as a percentage of revenue.	-2.5%	-11.5%	-27.0%	-60.9%	-34.9%	29.8%	15.6%	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$109.99M	-$66.07M	-$60.55M	-$41.39M	-$32.04M	-$27.57M	-$22.28M	-$3.87M	-$26979
Operating income as a percentage of revenue.	-401.7%	-243.6%	-394.5%	-625.5%	-1789.8%	-1910.4%	-1844.4%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$167.95M	-$63.56M	-$167000	-$44.16M	-$36.14M	-$29.25M	-$21.74M	-$3.71M	-$26979
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.00	$-1.00	$-1.09	$-1.02	$-1.00	$-1.00	$-1.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	–	–	–	–	–	–	–	–

Balance Sheet

	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2016-03-31	2014-07-31
Cash and highly liquid short-term investments the company can access almost immediately.	$24.40M	$43.10M	$80.48M	$88.32M	$44.31M	$30.15M	$14.82M	$2.73M	$9521
Everything the company owns that has value — cash, property, inventory, investments, and more.	$69.74M	$148.92M	$161.34M	$124.99M	$71.43M	$47.95M	$29.31M	$3.09M	–
All of the company's interest-bearing borrowings, short and long term combined.	$10.00M	$117000	$117000	$117000	$117000	$18.33M	$11.46M	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	–	$62.68M	–	$7.58M	$29.94M	$21.99M	$15.46M	$680999	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$57.09M	$86.24M	$103.43M	$117.41M	$41.49M	$25.95M	$13.85M	$2.41M	–

Cash Flow Statement

	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2016-03-31	2014-07-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$40.35M	-$44.82M	-$45.20M	-$29.36M	-$21.30M	-$17.67M	-$14.20M	-$2.79M	-$26979
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$5.99M	–	–	–	–	–	–	–	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$46.34M	–	–	–	–	–	–	–	–

	You	Peer avg
Revenue Growth	+111.4%	+9768.0%
ROE	–	-44.5%

Aktis Oncology, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison